OPKO Health (NASDAQ:OPK – Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.07, FiscalAI reports. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The firm had revenue of $163.58 million during the quarter, compared to analysts’ expectations of $131.23 million.
OPKO Health Trading Up 1.6%
Shares of OPK traded up $0.02 on Monday, reaching $1.24. 2,913,345 shares of the company’s stock were exchanged, compared to its average volume of 2,750,700. The business has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $1.26. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.61. The stock has a market capitalization of $936.31 million, a P/E ratio of -4.59 and a beta of 1.48. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28.
Analyst Ratings Changes
OPK has been the subject of several research reports. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings raised OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $1.55.
Institutional Trading of OPKO Health
Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in shares of OPKO Health by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock valued at $13,940,000 after purchasing an additional 67,973 shares during the period. Millennium Management LLC grew its stake in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after purchasing an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after purchasing an additional 3,600,378 shares during the period. AQR Capital Management LLC increased its holdings in OPKO Health by 466.7% in the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after purchasing an additional 1,324,988 shares during the last quarter. Finally, HRT Financial LP bought a new stake in OPKO Health in the fourth quarter valued at about $851,000. Institutional investors own 64.63% of the company’s stock.
OPKO Health Company Profile
OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.
In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.
Featured Stories
- Five stocks we like better than OPKO Health
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
